collaborations

Health Policy and the Opioid Epidemic

The opioid epidemic has claimed countless lives in the United States, and policy solutions may be useful in curbing it. This series of collaborations investigates the effects of health policies on opioid prescribing and treatment in the United States.

Cancer Biomarkers and Pharmacogenomics

A series of collaborations with cancer researchers at the University of Pennsylvania and the University of Michigan investigating associations between biomarkers, genes, tumor morphology, and outcomes.

[Abstract] Real-world time on treatment (rwTOT) with first-line (1L) enfortumab vedotin and pembrolizumab (EV+P) after U.S. Food and Drug Administration approval for advanced urothelial cancer (aUC)

ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium

Melanie Mayer, Nicholas J. Seewald, Ernesto Ulloa Perez, Blanca Homet Moreno, Chethan Ramamurthy, Aram Babcock, Haojie Li, Ronac Mamtani

[Abstract] Does liver tumor morphology predict outcomes after LDT, PRRT or captem?

Background: Patients with metastatic neuroendocrine tumor (NET) have multiple options for liver-directed therapy (LDT) and systemic …

Cathal O'Leary, David Tischfield, Rony Avritscher, Ghassan El-Haddad, Nicholas Fidelman, Ricardo Garcia-Monaco, Nimrata Vijayvergia, Pamela Kunz, Nicholas J. Seewald, Michael C. Soulen

[Abstract] LODESTAR: A Single Arm Phase II Study of Rucaparib in Solid Tumors with Pathogenic Germline or Somatic Variants in Homologous Recombination Repair (HRR) Genes

Purpose: Poly (ADP-ribose) polymerase inhibitors (PARPi) have proven clinical utility in platinum-sensitive breast, ovary, pancreas, …

Sriram Anbil, Nicholas J. Seewald, Kevin Lin, Marcia Craib, Christy Connor, Heidi Giordano, Karen McLachlan, Tanya Kwan, Lara Maloney, Hanna Tukachinsky, Alexa Schrock, Shuoguo Wang, Ethan Sokol, Brennan Decker, Katherine Nathanson, Susan Domchek, Kim Reiss

[Abstract] Association of BRCA1/2 pathogenic variants with primary tumor location and metastatic organotropism in pancreatic adenocarcinoma

Background: Pancreatic cancers (PDACs) with BRCA1/2 pathogenic variants (PVs) are prognostically favorable and predict response to …

Ryan Hood, Srishti Rathore, Nicholas J. Seewald, Kim Anna Reiss

[Abstract] Interaction of BRCA1 vs BRCA2 pathogenic variants with primary tumor location in pancreatic cancer

Background: BRCA1/2 germline or somatic pathogenic variants (PVs) are found in 5-10% of pancreatic adenocarcinoma (PDAC) patients. …

Ryan Hood, Nicholas J. Seewald, Srishti Rathore, Kim Anna Reiss

[Abstract] CYP3A4*22 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients

Background: Exemestane is a second generation steroidal aromatase inhibitor (AI) used for the treatment of estrogen receptor (ER) …

Daniel L. Hertz, Kelley M. Kidwell, Nicholas J. Seewald, Christina L. Gersch, Zeruesenay Desta, David A. Flockhart, Ana-Maria Storniolo, Vered Stearns, Todd C. Skaar, Daniel F. Hayes, N. Lynn Henry, James M. Rae"

[Abstract] Crossover from One Aromatase Inhibitor (AI) to Another in the Exemestane and Letrozole Pharmacogenetics (ELPh) Trial

Background: Tolerance of AI therapy can be poor due to treatment-emergent toxicities and can lead to early discontinuation …

Kunal C. Kadakia, Kelley M. Kidwell, Nicholas J. Seewald, Claire Frances Snyder, David A. Flockhart, Janet S. Carpenter, Julie L. Otte, Daniel F. Hayes, Anna Maria Storniolo, Vered Sterns, Norah Lynn Henry

[Abstract] Associations between treatment-emergent symptoms and early discontinuation of aromatase inhibitor (AI) therapy

ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I

Kunal C. Kadakia, Claire Frances Snyder, Kelley M Kidwell, Nicholas J. Seewald, Anna Maria Storniolo, David A. Flockhart, Janet S. Carpenter, Daniel F. Hayes, Vered Stearns, Norah Lynn Henry